Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.40 |
| ▸ | ITGAV | P06756 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672395 | 1.00 | ITGB3 (0.40) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL538358 | 0.88 | ITGB3 (0.39) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL538079 | 0.88 | ITGB3 (0.39) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL2045762 | 0.82 | OPRM1 (0.43) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL2050706 | 0.82 | OPRM1 (0.43) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL6418802 | 0.78 | ITGB3 (0.56) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL12922956 | 0.78 | ITGB3 (0.56) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL981179 | 0.78 | ITGB3 (0.56) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL981119 | 0.78 | ITGB3 (0.56) | ITGB3ITGA2BITGAVOPRM1OPRK1 | |
| SCHEMBL2043373 | 0.75 | ITGB3 (0.73) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628949-A4 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | claimed |
| JP-2006522139-A | — | — | 2006-09-28 | — | — | JP | claimed |
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| EP-1628949-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-01 | — | — | EP | claimed |
| WO-2004089890-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-21 | — | — | WO | claimed |
| EP-2257538-B1 | Process for the preparation of benzodiazepine derivatives | GLAXOSMITHKLINE LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8076475-B2 | Process | GLAXOSMITHKLINE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110015390-A1 | PROCESS | GLAXOSMITHKLINE LLC | 2011-01-20 | — | — | US | disclosed |
| EP-1628949-A4 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1628949-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-01 | — | — | EP | disclosed |
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004089890-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | CYP2E1, CYP1B1, CYP3A4 | ITGB3 3249/4885ITGA2B 1734/4885ITGAV 2835/4885 |
| US-20110015390-A1 | PROCESS | PTAFR, HCAR2, GPR142 | ITGB3 173/4885ITGA2B 182/4885ITGAV 200/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGA2B 191/4885ITGAV 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.